First dosing commenced for pivotal EMD-RX5 Phase 3 trial
Latest announcements
Announcement summary
First dosing commenced for pivotal EMD-RX5 Phase 3 trial
A major milestone for Emyria with dosing commencing for the Phase 3 Clinical Trial of Ultra-Pure CBD medication EMD-RX5 - a pivotal step towards our goal of TGA registration. EMD-RX5 aims to treat mild anxiety & stress and be available over the counter.
Take a look at this latest Q&A where Dr Michael Winlo answers some FAQs on Emyria's unique over-the-counter strategy and the competitive advantages it provides. "By analysing our real-world data, we can be really targeted on what dose form and what dose strength we think will be most effective and most likely to pass the rigorous examination of a clinical study.," he says.
We are the only group targeting symptoms of psychological distress in patients with chronic pain."
Ask a question
Your question will be sent privately to Emyria. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Emyria a question about this announcement.